Reduced BNT162b2 Messenger RNA Vaccine Response in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Naive Nursing Home Residents.

BNT162 Vaccine COVID-19 COVID-19 Vaccines Humans Nursing Homes RNA, Messenger SARS-CoV-2 Vaccines, Synthetic mRNA Vaccines
COVID-19 SARS-CoV-2 geriatrics vaccine

Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
06 12 2021
Historique:
received: 04 04 2021
pubmed: 17 5 2021
medline: 15 12 2021
entrez: 16 5 2021
Statut: ppublish

Résumé

After BNT162b2 messenger RNA vaccination, antibody levels to spike, receptor-binding domain, and virus neutralization were examined in 149 nursing home residents and 110 healthcare worker controls. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-naive nursing home residents' median post-second vaccine dose antibody neutralization titers are one-quarter that of SARS-CoV-2-naive healthcare workers.

Identifiants

DOI: 10.1093/cid/ciab447 PMID: 33993265 PMC: PMC8240817
pubmed: 33993265
pii: 6276391
doi: 10.1093/cid/ciab447
pmc: PMC8240817
doi:

Substances chimiques

COVID-19 Vaccines 0
RNA, Messenger 0
Vaccines, Synthetic 0
BNT162 Vaccine N38TVC63NU

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

2112-2115

Subventions

Organisme : NCI NIH HHS
ID : U01 CA260539
Pays : United States
Organisme : NIH HHS
ID : AI129709-03S1
Pays : United States
Organisme : BLRD VA
ID : I01 BX005507
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI129709
Pays : United States
Organisme : NIDA NIH HHS
ID : DP2 DA040254
Pays : United States

Commentaires et corrections

Type : UpdateOf

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.

Références

Vaccine. 2006 Feb 20;24(8):1159-69
pubmed: 16213065
Cell. 2021 Jan 21;184(2):476-488.e11
pubmed: 33412089
Immun Ageing. 2019 Sep 13;16:25
pubmed: 31528180
MMWR Morb Mortal Wkly Rep. 2021 Apr 30;70(17):639-643
pubmed: 33914720
Cell. 2021 Apr 29;184(9):2523
pubmed: 33930298
J Am Geriatr Soc. 2021 Aug;69(8):2063-2069
pubmed: 33861873
N Engl J Med. 2021 May 13;384(19):1824-1835
pubmed: 33440088
N Engl J Med. 2020 Dec 17;383(25):2439-2450
pubmed: 33053279
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
J Allergy Clin Immunol. 2020 May;145(5):1309-1321
pubmed: 32386655

Auteurs

David H Canaday (DH)

Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Geriatric Research, Education and Clinical Center, Cleveland Veterans Affairs Medical Center, Cleveland, Ohio, USA.

Lenore Carias (L)

Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.

Oladayo A Oyebanji (OA)

Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.

Debbie Keresztesy (D)

Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.

Dennis Wilk (D)

Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.

Michael Payne (M)

Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.

Htin Aung (H)

Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.

Kerri St Denis (K)

Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts, USA.

Evan C Lam (EC)

Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts, USA.

Christopher F Rowley (CF)

Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.

Sarah D Berry (SD)

Marcus Institute for Aging Research, Hebrew SeniorLife, Boston, Massachusetts, USA.

Cheryl M Cameron (CM)

Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.

Mark J Cameron (MJ)

Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.

Brigid Wilson (B)

Geriatric Research, Education and Clinical Center, Cleveland Veterans Affairs Medical Center, Cleveland, Ohio, USA.

Alejandro B Balazs (AB)

Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts, USA.

Stefan Gravenstein (S)

Division of Geriatrics and Palliative Medicine, Alpert Medical School of Brown University, Providence, Rhode Island, USA.
Center on Innovation in Long-Term Services and Supports, Providence Veterans Affairs Medical Center, Providence, Rhode Island, USA.

Christopher L King (CL)

Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Division of Infectious Diseases, Cleveland Veterans Affairs Medical Center, Cleveland, Ohio, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

Recherchemedicale.com › Facteurs biologiques › Antigènes › Vaccins synthétiques › Vaccins à base d'acide nucléique › Vaccins à ARNm › Vaccin BNT162 › Reduced BNT162b2 Messenger RNA Vaccine...
Recherchemedicale.com › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Pneumopathie infectieuse › Pneumopathie virale › COVID-19 › Reduced BNT162b2 Messenger RNA Vaccine...
Recherchemedicale.com › Mélanges complexes › Produits biologiques › Vaccins › Vaccins antiviraux › Vaccins contre la COVID-19 › Reduced BNT162b2 Messenger RNA Vaccine...
Recherchemedicale.com › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Reduced BNT162b2 Messenger RNA Vaccine...
Recherchemedicale.com › Établissements, main d'oeuvre et services de soins de santé › Établissements de santé › Établissements de soins de long séjour › Maisons de repos › Reduced BNT162b2 Messenger RNA Vaccine...
Recherchemedicale.com › Acides nucléiques, nucléotides et nucléosides › Acides nucléiques › ARN › ARN messager › Reduced BNT162b2 Messenger RNA Vaccine...
Recherchemedicale.com › Virus › Virus à ARN › Virus à ARN à brin positif › Nidovirales › Coronaviridae › Coronavirus › Betacoronavirus › Virus du SRAS › SARS-CoV-2 › Reduced BNT162b2 Messenger RNA Vaccine...
Recherchemedicale.com › Facteurs biologiques › Antigènes › Vaccins synthétiques › Reduced BNT162b2 Messenger RNA Vaccine...
Recherchemedicale.com › Facteurs biologiques › Antigènes › Vaccins synthétiques › Vaccins à base d'acide nucléique › Vaccins à ARNm › Reduced BNT162b2 Messenger RNA Vaccine...